196 related articles for article (PubMed ID: 38706775)
1. The role of chemoradiotherapy and immunotherapy in stage III NSCLC.
Orosz Z; Kovács Á
Pathol Oncol Res; 2024; 30():1611716. PubMed ID: 38706775
[TBL] [Abstract][Full Text] [Related]
2. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
Rajappa S; Sharma S; Prasad K
Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
[TBL] [Abstract][Full Text] [Related]
4. Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
Puri S; Saltos A; Perez B; Le X; Gray JE
Curr Oncol Rep; 2020 Mar; 22(4):31. PubMed ID: 32140986
[TBL] [Abstract][Full Text] [Related]
5. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer.
Cheema PK; Rothenstein J; Melosky B; Brade A; Hirsh V
Curr Oncol; 2019 Feb; 26(1):37-42. PubMed ID: 30853796
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.
Naidoo J; Antonia S; Wu YL; Cho BC; Thiyagarajah P; Mann H; Newton M; Faivre-Finn C
J Thorac Oncol; 2023 May; 18(5):657-663. PubMed ID: 36841540
[TBL] [Abstract][Full Text] [Related]
9. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
[TBL] [Abstract][Full Text] [Related]
10. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors.
Guberina M; Guberina N; Pöttgen C; Gauler T; Richlitzki C; Metzenmacher M; Wiesweg M; Plönes T; Forsting M; Wetter A; Herrmann K; Hautzel H; Darwiche K; Theegarten D; Aigner C; Schuler M; Stuschke M; Eberhardt WE
Immunotherapy; 2022 Aug; 14(12):927-944. PubMed ID: 35822656
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
Kaira K; Mouri A; Kato S; Yoshimura K; Kagamu H; Kobayashi K
BMC Cancer; 2020 Oct; 20(1):961. PubMed ID: 33023530
[TBL] [Abstract][Full Text] [Related]
13. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
[TBL] [Abstract][Full Text] [Related]
14. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Bozorgmehr F; Chung I; Christopoulos P; Krisam J; Schneider MA; Brückner L; Mueller DW; Thomas M; Rieken S
BMC Cancer; 2020 Aug; 20(1):806. PubMed ID: 32842974
[TBL] [Abstract][Full Text] [Related]
15. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
[TBL] [Abstract][Full Text] [Related]
16. Durvalumab for the treatment of non-small cell lung cancer.
Murakami S
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
[No Abstract] [Full Text] [Related]
17. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
Tachihara M; Tsujino K; Ishihara T; Hayashi H; Sato Y; Kurata T; Sugawara S; Shiraishi Y; Teraoka S; Azuma K; Daga H; Yamaguchi M; Kodaira T; Satouchi M; Shimokawa M; Yamamoto N; Nakagawa K;
JAMA Oncol; 2023 Nov; 9(11):1505-1513. PubMed ID: 37676681
[TBL] [Abstract][Full Text] [Related]
18. Role of immunotherapy in stage III nonsmall cell lung cancer.
Wrona A
Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337
[TBL] [Abstract][Full Text] [Related]
19. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy.
Zhou Q; Chen M; Wu G; Chang JH; Jiang O; Cui JW; Han G; Lin Q; Fang J; Chen GY; Wu YL
Transl Lung Cancer Res; 2020 Oct; 9(5):2008-2015. PubMed ID: 33209620
[TBL] [Abstract][Full Text] [Related]
20. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer.
Kashihara T; Nakayama Y; Okuma K; Takahashi A; Kaneda T; Katagiri M; Nakayama H; Kubo Y; Ito K; Nakamura S; Takahashi K; Inaba K; Murakami N; Saito T; Okamoto H; Itami J; Kusumoto M; Ohe Y; Igaki H
Radiother Oncol; 2023 Mar; 180():109454. PubMed ID: 36640944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
